265 related articles for article (PubMed ID: 32017214)
21. Marginal Zone Lymphoma Manifesting as Macrophage Activation Syndrome: A Case Report.
Ebrahimi N; Noor SM; Kordasti S; Akhtari M; Norouzi S; Vakhshoori M; Abdipour A
J Investig Med High Impact Case Rep; 2024; 12():23247096241244732. PubMed ID: 38577998
[TBL] [Abstract][Full Text] [Related]
22. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS).
Shakoory B; Geerlinks A; Wilejto M; Kernan K; Hines M; Romano M; Piskin D; Ravelli A; Sinha R; Aletaha D; Allen C; Bassiri H; Behrens EM; Carcillo J; Carl L; Chatham W; Cohen JI; Cron RQ; Drewniak E; Grom AA; Henderson LA; Horne A; Jordan MB; Nichols KE; Schulert G; Vastert S; Demirkaya E; Goldbach-Mansky R; de Benedetti F; Marsh RA; Canna SW
Arthritis Rheumatol; 2023 Oct; 75(10):1714-1732. PubMed ID: 37486733
[TBL] [Abstract][Full Text] [Related]
23. Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.
Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Yachie A
Clin Exp Immunol; 2018 Mar; 191(3):349-355. PubMed ID: 28815559
[TBL] [Abstract][Full Text] [Related]
24. Hemophagocytic lymphohistiocytosis: when the immune system runs amok.
Janka G
Klin Padiatr; 2009 Sep; 221(5):278-85. PubMed ID: 19707989
[TBL] [Abstract][Full Text] [Related]
25. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Boom V; Anton J; Lahdenne P; Quartier P; Ravelli A; Wulffraat NM; Vastert SJ
Pediatr Rheumatol Online J; 2015 Dec; 13():55. PubMed ID: 26634252
[TBL] [Abstract][Full Text] [Related]
26. Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.
Henderson LA; Cron RQ
Paediatr Drugs; 2020 Feb; 22(1):29-44. PubMed ID: 31732958
[TBL] [Abstract][Full Text] [Related]
27. Macrophage activation syndrome in the era of biologic therapy.
Grom AA; Horne A; De Benedetti F
Nat Rev Rheumatol; 2016 May; 12(5):259-68. PubMed ID: 27009539
[TBL] [Abstract][Full Text] [Related]
28. An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
Arduini A; Marasco E; Marucci G; Pardeo M; Insalaco A; Caiello I; Moneta GM; Prencipe G; De Benedetti F; Bracaglia C
Pediatr Rheumatol Online J; 2019 May; 17(1):25. PubMed ID: 31118063
[TBL] [Abstract][Full Text] [Related]
29. Variation of Diagnostic Approaches and Treatment Practices for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome Among Pediatric Subspecialists.
Carter-Febres M; Lozano-Chinga M; Thomsen W; Treemarcki EB; James KE; Fluchel M
J Pediatr; 2023 Apr; 255():65-71.e6. PubMed ID: 36328191
[TBL] [Abstract][Full Text] [Related]
30. Unmasking of systemic lupus erythematosus in a patient with hemophagocytic lymphohistiocytosis- macrophage activation syndrome (HLA-MAS) and diffuse alveolar hemorrhage.
Sukhadiya P; Kumar P; Meena DS; Kumar P H A; Vijayan N; Garg P; Garg MK
Reumatismo; 2023 Mar; 74(4):. PubMed ID: 36942984
[TBL] [Abstract][Full Text] [Related]
31. Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review.
Charlesworth JEG; Kavirayani A
Eur J Haematol; 2023 Sep; 111(3):458-476. PubMed ID: 37344166
[TBL] [Abstract][Full Text] [Related]
32. [Macrophage activation syndrome complicating family lymphohistiocytosis].
Boussaadni YE; Benajiba N; Bousfiha AA; Ailal F
Pan Afr Med J; 2017; 26():93. PubMed ID: 28491224
[TBL] [Abstract][Full Text] [Related]
33. An Evidence-Based Guideline Improves Outcomes for Patients With Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome.
Taylor ML; Hoyt KJ; Han J; Benson L; Case S; Chandler MT; Chang MH; Platt C; Cohen EM; Day-Lewis M; Dedeoglu F; Gorman M; Hausmann JS; Janssen E; Lee PY; Lo J; Priebe GP; Lo MS; Meidan E; Nigrovic PA; Roberts JE; Son MBF; Sundel RP; Alfieri M; Yeun JC; Shobiye DM; Degar B; Chang JC; Halyabar O; Hazen MM; Henderson LA
J Rheumatol; 2022 Sep; 49(9):1042-1051. PubMed ID: 35840156
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP).
Sandler RD; Tattersall RS; Schoemans H; Greco R; Badoglio M; Labopin M; Alexander T; Kirgizov K; Rovira M; Saif M; Saccardi R; Delgado J; Peric Z; Koenecke C; Penack O; Basak G; Snowden JA
Front Immunol; 2020; 11():524. PubMed ID: 32296434
[No Abstract] [Full Text] [Related]
35. Hemophagocytic lymphohistiocytosis in adults: diagnosis and treatment.
Larroche C
Joint Bone Spine; 2012 Jul; 79(4):356-61. PubMed ID: 22464018
[TBL] [Abstract][Full Text] [Related]
36. Cytokine Storm Syndrome.
Cron RQ; Goyal G; Chatham WW
Annu Rev Med; 2023 Jan; 74():321-337. PubMed ID: 36228171
[TBL] [Abstract][Full Text] [Related]
37. Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report.
Peterlin P; Garnier A; Le Bourgeois A; Jullien M; Seguin A; Eveillard M; Béné MC; Guillaume T; Chevallier P
Acta Haematol; 2022; 145(5):537-541. PubMed ID: 35724631
[TBL] [Abstract][Full Text] [Related]
38. The genetics of macrophage activation syndrome.
Schulert GS; Cron RQ
Genes Immun; 2020 May; 21(3):169-181. PubMed ID: 32291394
[TBL] [Abstract][Full Text] [Related]
39. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.
Wang D; Chen XH; Wei A; Zhou CJ; Zhang X; Ma HH; Lian HY; Zhang L; Zhang Q; Huang XT; Wang CJ; Yang Y; Liu W; Wang TY; Li ZG; Cui L; Zhang R
Orphanet J Rare Dis; 2022 Apr; 17(1):151. PubMed ID: 35379272
[TBL] [Abstract][Full Text] [Related]
40. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis.
Karakike E; Giamarellos-Bourboulis EJ
Front Immunol; 2019; 10():55. PubMed ID: 30766533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
